AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
Returns on capital
AgomAb Therapeutics N.V. American Depositary Shares management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
0.0%
avg 0.0%
ROIC
0.0%
avg 0.0%
ROA
0.0%
avg 0.0%
Analysis
ROE is currently the strongest return metric at 0.0% versus its period average of 0.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Andrea Sáez Borderías | Chief Development Officer | — | 44 | — | — |
Paul Van Der Horst | Chief Business Officer | — | 38 | — | — |
Tim Knotnerus | CEO & Executive Director | — | 43 | — | — |
Paolo Michieli | Founder, Senior Advisor & Member of Scientific Advisory Board | — | — | — | — |
Pierre Kemula | Chief Financial Officer | — | 52 | — | — |
Philippe Wiesel | Chief Medical Officer | — | 59 | — | — |
Ellen Lefever | General Counsel | — | 41 | — | — |
Sofie Van Gijsel | Vice President of Investor Relations | — | — | — | — |
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
13
$503,470.00
Sells
0
$0.00
Net Transaction Value
+$503,470.00
Net buying
Most Active
Epstein David R
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 5, 26Nov 5, 2026 | Epstein David R Direct | Buy | $34.6K$34,550.00 |
| Nov 5, 26Nov 5, 2026 | Epstein David R Direct | Buy | $34.9K$34,900.00 |
| Nov 5, 26Nov 5, 2026 | Epstein David R Direct | Buy | $34.1K$34,050.00 |
| Oct 21, 26Oct 21, 2026 | Epstein David R Direct | Buy | $44.5K$44,500.00 |
| Oct 21, 26Oct 21, 2026 | Epstein David R Direct | Buy | $44.3K$44,300.00 |
| Oct 8, 26Oct 8, 2026 | Epstein David R Direct | Buy | $44.5K$44,500.00 |
| Oct 6, 26Oct 6, 2026 | Kemula Pierre Thadee Victor Direct | Buy | $17.1K$17,080.00 |
| Oct 6, 26Oct 6, 2026 | Epstein David R Direct | Buy | $43.5K$43,500.00 |
| Oct 6, 26Oct 6, 2026 | Kemula Pierre Thadee Victor Direct | Buy | $42.9K$42,850.00 |
| Oct 6, 26Oct 6, 2026 | Kemula Pierre Thadee Victor Direct | Buy | $26K$26,010.00 |
1–10 of 13
Summary
Insiders reported 13 buys worth $503,470.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $503,470.00. Epstein David R was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does AgomAb Therapeutics N.V. American Depositary Shares compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about AGMB's management, answered from reported figures.
Who manages AGMB?
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) lists 8 active executives. The top listed executive is Andrea Sáez Borderías, Chief Development Officer.
Are AGMB insiders buying or selling?
Recent insider activity shows net buying of $2.09M.
Continue the stock analysis
Jump to another research area for this company.